Cooperative Agreement U01CA282163
Award Date
9/9/24
Completion Date
8/31/29
Dollars Obligated
$647K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $419,133 to Massachusetts Institute of Technology (MIT) to advance the development of patient ascites therapeutic response biosensors. The project aims to overcome key bottlenecks in cancer drug resistance by leveraging patient ascites, a plentiful and molecularly representative sample format, to evaluate cell identities and therapeutic sensitivities using a...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Beckman Research Institute of the City of Hope to investigate the use of transcriptome dynamics and leukemia potential as a dynamic biomarker to design adaptive treatment approaches for acute myeloid leukemia (AML). The key objectives are to: 1) Quantify leukemia potential dynamics driven by different oncogenic signals in murine models, 2) Evaluate the effects of...
The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...
This $679,188 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop liquid biopsy tools using artificial intelligence-assisted isolation of tumor cells from malignant effusions to evaluate known biomarkers and discover new predictive biomarkers and drug targets for metastatic breast cancer. The project will first validate the DeepCell AI-assisted platform to isolate circulating tumor cells from malignant effusions, then use...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The goal is to establish multiple levels of hypoxia within the tumor-chip, investigate spatiotemporal interaction between the tumor microenvironment and cancer-immune cells during...
This Project Grant award of $542,663 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research aimed at developing novel targeted therapies for acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The key objectives are to: Determine the preclinical efficacy of BRG1/BRM antagonists, including an inhibitor (FHD-286) and a degrader (AU15330), and assess their impact on the epigenome,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $458,698 in funding to the Regents of the University of Michigan to conduct research aimed at identifying novel gene drivers underlying therapy resistance and competitive growth of acute myeloid leukemia (AML) cells, which can lead to disease relapse. The key objectives are to functionally validate new genes that contribute to AML relapse and therapy resistance, given that overcoming...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The award period runs from September 12, 2024 to August 31, 2026. The purpose of this Project Grant is to develop a novel assay and artificial intelligence (AI) model for the early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using a novel...
The National Cancer Institute (NCI) awarded a $872,555 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the Dana-Farber Cancer Institute, Inc. (DFCI) to enhance and further develop informatics methods for long-read cancer sequencing. The key objectives are to: 1) Improve existing methods for long-read analysis, including long-read alignment, assembly, and downstream bioinformatic tools for somatic variant discovery; 2) Generate a resource of long-read cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $402,600.00 to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key products and services to be delivered under this 5-year award include: Testing the efficacy and safety of CAR T-cells targeting the...